Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Xcyte Digital Corp. Signs Agreement to Purchase Assets of Webinar.net (click to learn more) Viva Gold Reports Multiple High-Grade Gold Hits at the Tonopah Gold Project (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Intelgenx Technologies Corp IGXT


Primary Symbol: T.IGX

Healthcare
IntelGenx Technologies Corp. is a Canada-based drug delivery company. The Company provides single-site, end-to-end contract development and manufacturing services of oral thin film and transdermal drug products for the pharmaceutical and animal health markets, spanning the entire drug development and commercial product cycle. The Company’s film technologies, including VersaFilm, DisinteQ... see more

Recent & Breaking News (TSX:IGX)

IntelGenx Announces Closing of First Tranche of Non-Brokered Private Placement From Strategic Partner for Approximate Aggregate Gross Proceeds of US$3 Million (Including US$750,000 to be Received by the Company Once Shareholder Approvals Have Been Obtained)

GlobeNewswire August 31, 2023

IntelGenx Reports Second Quarter 2023 Financial Results

GlobeNewswire August 14, 2023

IntelGenx Announces First Agreement for CDMO Packaging Services

GlobeNewswire August 10, 2023

IntelGenx to Report Second Quarter 2023 Financial Results on August 14, 2023 - Conference Call to Follow

GlobeNewswire August 7, 2023

IntelGenx Completes Enrollment for 'BUENA' Montelukast VersaFilm® Phase 2a Clinical Trial in Patients with Mild to Moderate Alzheimer's Disease

GlobeNewswire August 1, 2023

IntelGenx Provides Update on Research Collaboration Evaluating Montelukast VersaFilm® for the Treatment of Parkinson's Disease

GlobeNewswire July 25, 2023

IntelGenx Announces a Change to its Board of Directors

GlobeNewswire July 21, 2023

IntelGenx Announces Voting Results on Election of Directors

GlobeNewswire July 6, 2023

IntelGenx Unveils Short-Term Commercial Objectives

GlobeNewswire May 31, 2023

IntelGenx Receives Amended DEL License to Conduct Third-Party Testing

GlobeNewswire May 17, 2023

IntelGenx Reports First Quarter 2023 Financial Results

GlobeNewswire May 11, 2023

IntelGenx to Report First Quarter 2023 Financial Results on May 11, 2023 - Conference Call to Follow

GlobeNewswire May 4, 2023

IntelGenx Extends Period to Exercise Certain Warrants

GlobeNewswire April 27, 2023

IntelGenx Announces Receipt of Complete Response Letter from the FDA for Xiromed-Partnered Buprenorphine Buccal Film

GlobeNewswire April 27, 2023

IntelGenx Announces FDA Approval of RIZAFILM® for the Treatment of Acute Migraine

GlobeNewswire April 17, 2023

IntelGenx Announces Organizational Changes to Support Global Growth Strategy

GlobeNewswire April 13, 2023

IntelGenx Reports Fourth Quarter and Full-Year 2022 Financial Results

GlobeNewswire March 29, 2023

IntelGenx Revises Fourth Quarter and Full Year 2022 Financial Results Reporting and Conference Call Date to March 29, 2023

GlobeNewswire March 24, 2023

IntelGenx to Report Fourth Quarter and Full Year 2022 Financial Results on March 30, 2023 - Conference Call to Follow

GlobeNewswire March 23, 2023

IntelGenx Announces Closing of Notes Offering

GlobeNewswire March 21, 2023